ArticleACS omega2026
On-Site Microfluidic Assay for the Detection of Multiple Drugs in Urine.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunoassays are widely used for preliminary drug screening. While lateral flow assays (LFAs) offer rapid and portable testing, they often suffer from limited sensitivity and subjective interpretation. In contrast, laboratory-based immunoassay systems provide high precision but are unsuitable for field use due to their size and cost. To address these limitations, we developed a portable fluorescence-based microfluidic assay capable of detecting methamphetamine (MET), benzoylecgonine (BE), 11-nor-9-carboxy-tetrahydrocannabinol (THC-COOH), and benzodiazepines (BZOs) in urine specimens within 5 min. They were selected based on both global and domestic prevalence, as well as the detection capability of the developed microfluidic chip, which was designed to simultaneously target all four. The assay comprises a portable reader and a chip with two channels, each aligned with drug-specific antibodies, enabling simultaneous detection. The assay was tested against standard concentrations of the target drugs, delivering accurate test/reference ratios and signal displacements at threshold levels. We evaluated urine specimens (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.